<- Go Home
Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Market Cap
$590.7M
Volume
1.1M
Cash and Equivalents
$21.4M
EBITDA
-$88.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$67.5M
Profit Margin
N/A
52 Week High
$5.70
52 Week Low
$2.59
Dividend
N/A
Price / Book Value
2.96
Price / Earnings
-6.63
Price / Tangible Book Value
3.14
Enterprise Value
$397.6M
Enterprise Value / EBITDA
-4.48
Operating Income
-$88.9M
Return on Equity
47.95%
Return on Assets
-26.39
Cash and Short Term Investments
$219.9M
Debt
$26.8M
Equity
$199.3M
Revenue
N/A
Unlevered FCF
-$48.1M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium